<DOC>
	<DOCNO>NCT01983540</DOCNO>
	<brief_summary>This follow-up primary series vaccination schedule Study A3L24 ( NCT01177722 ) booster vaccination Study A3L27 ( NCT01444781 ) . Study Objective : - To describe long-term antibody persistence 3.5 4.5 year age follow 3-dose primary series vaccination either DTaP-IPV-Hep B-PRP-T+Prevenar™ ( PCV7 ) +Rotarix™ Infanrix hexa™+Prevenar™ ( PCV7 ) +Rotarix™ vaccination 2 , 4 , 6 month age booster vaccination DTaP-IPV-Hep B-PRP-T+Prevenar™ ( PCV7 ) Infanrix hexa™+Prevenar™ ( PCV7 ) 12 24 month age . Observational Objectives : - To describe long-term antibody persistence group stratification age inclusion A3L27 booster study . - To describe effect one additional oral dose stand alone poliovirus isotypes 1 , 2 3 vaccine* antibody persistence immune response poliovirus isotypes ( 4 vs 5 dos poliovirus administer ) .</brief_summary>
	<brief_title>Antibody Persistence Age 3.5 4.5 Years After Primary Booster DTaP-IPV-Hep B-PRP~T Infanrix Hexa Vaccination</brief_title>
	<detailed_description>No investigational vaccine administer study . Subjects previously randomize complete primary series , Study A3L24 booster study A3L27 invite take part study . Any serious adverse event ( SAEs ) relate vaccine administer precede trial ( A3L27 ; ) SAEs relate A3L28 study procedure collect throughout trial . No vaccine administer part study .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Aged 3 year half ( 42 month ± 60 day ) day first study visit Informed consent form sign dated parent ( ) legally acceptable representative ( independent witness/es require local regulation ) Subject parent/legally acceptable representative able attend schedule visit comply trial procedure Receipt primary vaccination 3 dos investigational vaccine primary series trial A3L24 ( either DTaPIPVHep BPRPT Infanrix hexa , concomitantly administer Prevenar [ PCV7 ] Rotarix ) booster dose trial A3L27 ( either DTaPIPVHep BPRPT Infanrix hexa , concomitantly administer Prevenar [ PCV7 ] ) . Participation time study enrollment ( 4 week precede first trial visit ) plan participation present trial period another clinical trial investigate vaccine , drug , medical device , medical procedure Incomplete primary booster immunization trial A3L24 A3L27 Receipt vaccine 4 week precede first trial visit plan receipt vaccine 4 week precede second trial visit Previous vaccination diphtheria , tetanus , pertussis , poliomyelitis , hepatitis B , Haemophilus influenzae type b infection vaccine ( ) completion A3L27 study Receipt immune globulin , blood bloodderived product past 3 month Known suspected congenital acquire immunodeficiency ; receipt immunosuppressive therapy , anticancer chemotherapy radiation therapy , within precede 3 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) History diphtheria , tetanus , pertussis , poliomyelitis , hepatitis B , Haemophilus influenzae type b infection ( ) , confirm either clinically , serologically , microbiologically completion trial A3L27 Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate blood drawn Acute chronic illness , opinion Investigator , stage might interfere trial conduct completion .</criteria>
	<gender>All</gender>
	<minimum_age>42 Months</minimum_age>
	<maximum_age>54 Months</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Diphtheria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Whooping Cough</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>Poliomyelitis</keyword>
	<keyword>Pediatric combine vaccine</keyword>
</DOC>